Journal
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
Volume 5, Issue 6, Pages 659-669Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ECI.09.38
Keywords
allergic rhinitis; azelastine nasal spray; intranasal corticosteroid; nonallergic rhinitis; oral antihistamine
Categories
Ask authors/readers for more resources
Rhinitis affects millions of people around the world, places a huge burden on the economy and reduces patients' health-related quality of life. Azelastine nasal spray is a second-generation antihistamine, indicated for the treatment of allergic and nonallergic rhinitis in both adults and children. It offers a rapid onset of action (15 min) and flexibility of both dose (i.e., one or two sprays/nostril twice daily) as well as dosage (i.e., fixed or as needed). Compared with other agents used to treat allergic rhinitis, azelastine nasal spray exhibits superior efficacy to oral antihistamines (e.g., desloratadine and cetirizine), other intranasal antihistamines (e.g., levocabastine) and the intranasal corticosteroid mometasone furoate, and comparable efficacy to the potent intranasal corticosteroid fluticasone propionate (FP). Combination therapy with intranasal FP has the potential to enhance clinical benefit, as the combination of azelastine and FP nasal sprays reduce symptoms in allergic rhinitis patients more than either agent alone. Azelastine nasal spray has an excellent safety profile.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available